BioPharma Resources

Drug Trial Radar · NCT02805023

BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)

Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jun 2016

Primary completion

Jul 2017

Study completion Dec 2027

Sponsor

Lead sponsor
BioGenCell Ltd.Biogen (BIIB)
Sponsor type
Industry
Collaborators
Laniado Hospital; Rabin Medical Center
First posted
Jun 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral arterial disease (PAD) with critical limb ischemia (CLI) who have not responded to optimal pharmacological treatment or control of risk factors and/or had a revascularization failure, and do not have the option of further revascularization treatment.

Conditions

  • Chronic Limb-Threatening Ischemia
  • Peripheral Arterial Disease
  • Peripheral Vascular Disease

Interventions

  • BGC101 (autologous EnEPC preparation)Biological

    Intramuscular injections - single treatment session

  • Control mediumBiological

    Intramuscular injections - single treatment session

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (Incidence of adverse events)Time frame: 12 Months
  2. Efficacy (Improvement of indication signs)Time frame: 12 Months

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • University of San Francisco

    San Francisco, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Rambam Health Care Campus

    Haifa, Israel

  • Laniado Hospital

    Netanya, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.